Serenex Announces Initiation of Phase 1 Trial for Oral Hsp90 Inhibitor, SNX-5422
DURHAM, NC -- (MARKET WIRE) -- May 31, 2007 -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, today announced the initiation of a phase 1 trial for SNX-5422, its novel heat shock protein 90 (Hsp90) inhibitor. SNX-5422 is a small molecule delivered orally and was discovered internally using Serenex's proprietary chemoproteomics technology platform.